How much super do Australians need to retire? It could be less than you think
The ASFA retirement standard breaks down the cost of retirement, examining health insurance, basic living expenses, and other essential costs. According to estimates for the March 2025 quarter, a household with a 'comfortable lifestyle' — including a reasonable car, health insurance and an overseas trip — spends $73,875 per year for a couple who own their home and about $52,383 for a single homeowner.
In contrast, those living a 'modest lifestyle', the estimated annual budget was approximately $15,000 lower for singles than for couples living in their own home, typically spending less on health insurance, cars, and taking fewer holidays, among other expenses. While for renters living a 'modest lifestyle', a couple was estimated to have spent $64,259 and a single person $46,663 annually. Someone on the age pension is estimated to spend $29,024 per year, and a couple $43,753, with both figures including supplements.
ASFA CEO Mary Delahunty attributed the rise in retirement affordability to higher super contributions. From July, employers will be required to pay 12 per cent of their employees' wages in superannuation, an increase of 0.5 per cent. "With the 12 per cent super guarantee coming in, we can now say that the system foundations are cemented for young, working people to have a comfortable retirement. It's a moment all Australians should be proud of," Delahunty said.
Joey Moloney, the deputy director of the housing and economic security program at the Grattan Institute, told SBS News the real cost of retirement could be even lower, as retirees typically spend less once they stop working. "When you look at people's spending habits from pre-retirement to post-retirement, what you see is that people spend less in retirement and increasingly so as retirement goes on," he said. "Pensioners benefit from a bunch of discounts on council rates, electricity, medicines and other benefits that add up to an implicit income of thousands of dollars a year."
For people who have paid off their mortgage, they could have an extra 30 per cent of their income freed up rather than going into repayments, Moloney said. He said most people who own their own homes would have a secure retirement, but the situation is different for renters. "What the data shows is that renters in retirement are actually typically doing it tough. Poverty rates are pretty high, and levels of reported financial stress are pretty high."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
21 minutes ago
- News.com.au
Health Check: Pro Medicus banks the profits as customers go the ‘full stack'
Pro Medicus shares surge up to 7% on record revenue and earnings Tetratherix pockets $3.3 million, while Rhythm girds for a raising CEO oration inspires Starpharma share run The $32 billion market cap ProMedicus (ASX:PME) has drawn the chapter on what co-founder and CEO Dr Sam Hupert dubs 'the most successful year in the company's history by any measure'. The US-focused radiology imaging house today posted revenue of $213 million for the full year to June 30 2025, up 32%. Net earnings surged 39%, to $115 million. While the numbers were pretty much as expected, the shares surged up to 7% on the prospect of further revenue gains from newly-written contracts. The company is also expanding into areas such as cardiology and pathology – the latter of which could be two-thirds the size of the radiology market. "But it's early days." Hupert describes a 'record year of new contract wins, contract renewals and sales of additional modules'. Revenue rose in the three key jurisdictions of the US, Germany and Australia, but North America led the way with a 36% increase. The company derives about 90% of its revenue from the US. During the year, Pro Medicus won $520 million of new contracts. Yep, that's a record. These included a monster $330 million deal with Trinity Health, one of the biggest not-for-profit networks in the US. The company also signed two key renewals, totalling $130 million. Hupert says more customers are going the 'full stack', which means they are availing of the company's image viewing, archiving and workflow tools. Only the beginning? He adds that many of the recently signed contacts will come on stream 'in the next year and beyond', which means 98% of this revenue is yet to be recognised. He cites forward contracted revenue for the next five years at $948 million, up from $624 million a year ago. Despite the growth, Pro Medicus still accounts for only 10% of the US total addressable market. The company still trades on an extravagant price-earnings multiple, which implies that this 10% will become a much bigger number in the near future. 'We don't have a fixed target in mind, our aim is to get as big a percentage market share as possible,' Hupert says. 'Importantly, we do not see any technical or capacity-related reason why we will not continue to increase our market share materially from here.' Hupert says the company's recent $10 million loan facility to lung imager 4D Medical (ASX:4DX) related to the companies AI capabilities. There's the prospect of adding one or morr 4D products to the Pro Medicus stable. "But I wouldn't read more into it than that." Broker RBC says while the result was broadly in line with consensus, the company pleased with its free cash flow generation and upbeat outlook on contracts. RBC has a 'hold' rating on the stock with a 'price target' of $350. Starpharma shares take a run Starpharma (ASX:SPL) CEO Cheryl Maley's prezzo to Bioshares annual summit in Hobart last week appears to have been enough to spark a 50% share run. The contents weren't new, but Maley did outline how management had tweaked the company's strategy over the last year. Maley started in January 2024. Otherwise, Starpharma's June quarterly report showed customer receipts of $2 million, 51% higher than the March quarter. Net cash outflows were $2 million. Starpharma's reason for being is its dendrimer enhanced product (DEP) platform, which has produced the commercialised bacterial vaginosis treatment Vivagel and the germ-busting nasal spray Viraleze. Before you ask, dendrimers are nanoscale polymers aimed at improving drug efficacy and reducing side effects (such as bone marrow toxicity and hair loss). The company has oncology programs that combine the dendrimer with three existing drugs. They are irinotecan (colorectal cancer), cabazitaxel (prostate cancer and others). Management is attempting to outlicense these assets. Maley says despite considerable interest 'the licensing process has taken longer than anticipated.' She attributes this to factors including "the evolving oncology landscape shifting towards targeted treatment options and the current geo-political environment, which has impacted the biotechnology industry at large". Starpharma ended the quarter with cash of $15.5 million – enough funding for close to two years – with an expected $3.5 million R&D tax rebate yet to come. Starpharma shares today had a well-earned rest, falling around 10%. Rhythm limbers up for raising Rhythm Biosciences (ASX:RHY) shares are on trading halt pending a capital raising announcement, on or before next Monday. It's not a bad time for the company to tap the market, given its shares have gained 75% over the last month. Rhythm is developing Colostat, a blood-based cancer assay which could replace the commonly used 'poo' tests. The company also owns Genetype, a genetic risk assessment testing platform combining clinical, family history and genetic data. Rhythm bought this asset from the administrators of Genetic Technologies. Tetratherix gets a grant Of course, the best form of funding is the free variety and the recently listed Tetratherix (ASX:TTX) has come up trumps in this regard. The wound-care house has been awarded $3.3 million of non-dilutive funding, under the federal Industry Growth Program grant. Tetratherix is commercialising products based on its polymer biomaterials, which offer claimed benefits such as increased flexibility and bioresorbability. The grant will partly fund a $7.4 million project to take its Tetramatrix platform global, including expanding its production facility near Sydney Airport. The funding spans the current financial year and 2026-27. Tetratherix shares have gained a sprightly 40% since listing on June 30, the only local life sciences IPOs year to date. But if you think that's a drought, there been no US biotech IPO for six months. The last one was diseases specialist Aardvark Therapeutics, which listed on the Nasdaq in mid-February.
News.com.au
an hour ago
- News.com.au
Average family's grocery bill up 11 per cent, research finds
The average family shop has gone up 11 per cent in the past year, the largest increase in five years. Comparison website Canstar found that after polling 2800 shoppers the average weekly shop for a household of four people had risen by $25 to $240. 'That's a big jump for a non-negotiable purchase,' CanstarBlue spokeswoman Eden Radford said. 'Every move, no matter how small, can make a difference, particularly when the average weekly spend for a household of four at the supermarket has climbed 11 per cent from the previous year to hit $240.' A household of four people is now spending $12,480 a year at the supermarket, the analysis finds. Almost half of the people surveyed (45 per cent) go to two of either Aldi, Coles, IGA or Woolworths, 16 per cent visit at least three of these, while 39 per cent are loyal to just one. More than 80 per cent of respondents also said they changed their shopping habits in the past year to try and save money; most commonly spending more time checking the unit price, buying in bulk, buying marked-down items closer to expiry, only buying in-season produce, cutting out treats, and buying frozen vegetables instead of fresh. 'When shoppers were asked what they think was the most important thing a supermarket should offer them, the majority (63 per cent) said it was low prices across all products, not just specials,' the researchers said. 'This response was far ahead of the second most popular response of convenience. 'The results demonstrate that while shoppers might enjoy a supermarket that offers easy parking and access, ultimately it's the impact on their budget that they're concerned about most.' The survey also took answers on overall satisfaction, value, produce freshness and customer experience at the four major outlets. Aldi won Canstar's 'most satisfied customer award' for the eighth year in a row. 'Supermarket shoppers rated Aldi a top rating of five stars for overall satisfaction as well as value for money, freshness of fruit, vegetables, and meat, store/website layout and presentation, and quality of supermarket-owned branded products,' the research found. 'The only other supermarkets to score a top rating of five stars from shoppers were IGA, for customer service and checkout experience, and Woolworths, which earned five stars for its product range.' While Canstar's data indicates the average shopper's weekly haul has increased by $25, or 11 per cent, the latest government data shows fruit and vegetable prices rose 4.6 per cent in the 12 months to the June quarter. Global shortages of cocoa have driven up chocolate prices, while bird flu outbreaks in Australia drastically drove up egg prices during the past year. As a whole, food and non-alcoholic beverage prices have risen 3 per cent in the past 12 months, the government data shows, meat and seafood is up 3 per cent, and bread and cereal products have risen 2.2 per cent.
News.com.au
an hour ago
- News.com.au
Surf's up for Surfection founder with circa $23m sale
Surfection founder Chris Athas has been in the line-up waiting to sell his Mosman home but at last after almost a year on-and-off the market he is out of the calm and caught a buyer. The keen surfer and northside businessman has sold his Golden Mile designer home at the upper end of its $22m-$24m guide. The north-facing home in Hopetoun Ave listed last year with $28m expectations, then switched agencies and had $6m carved off its asking price before returning in April to local agent Michael Coombs, director of Atlas Lower North. In April the luxury Burton Katon Halliday home was advertised with a $22m-$24m guide and while Coombs wouldn't be drawn on a sales figure word on the street is that it did trade at the top end of that guide. Chris and his wife Amanda bought the address in 2001 for $3.965m before engaging the renowned architects to create a world-class home suitable for a family of six and regular entertaining. The home has five bedrooms, six bathrooms, a four-car garage and is just 250m from Chinaman's Beach. Earlier this month it was revealed a house next to Chinaman's Beach, in McLean Cres, sold quietly for $43m. Coombs said a couple of buyers were interested in 1B Hopetoun Ave with its northerly harbour views, pool, wine cellar and lift and it sold to a north shore family. 'I think Spring is going to be busy this year,' he said. 'We have eight or ten properties launching and there are buyers out there.' The surfing retail chain Surfection started in Mosman in 1985 but Chris also has hospitality business interests in Manly. He and Amanda are downsizing.
